This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    30/06/19

    Primary care of asthma: new options for severe eosinophilic asthma.

    This paper reviews asthma assessment in primary care and describes the pathophysiology, clinical characteristics and new targeted treatments available for patients with severe eosinophilic asthma.

    • Source: Current Medical Research and Opinion
    Journals
    Journal
    26/05/19

    Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice.

    Background: Asthma is an inflammatory disease of the airways with symptoms that vary over time and intensity, sometimes leading to disability or even death. Eosinophilic asthma accounts for 25% of cases of severe asthma.

    • Source: Drugs in Context
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/09/14

    Positive studies MENSA and SIRIUS of mepolizumab for Asthma- GSK

    Results published in the New England Journal of Medicine (NEJM) and presented at the European Respiratory Society (ERS) congress provide...

    Journals
    Journal
    01/11/19

    Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.

    Objective: We sought to assess the long-term safety, efficacy, and pharmacodynamics of mepolizumab in children aged 6 to 11 years with severe asthma with an eosinophilic phenotype.

    • Source: The Journal of Allergy and Clinical Immunology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    06/11/15

    FDA approves Nucala (mepolizumab) to treat severe asthma- GSK

    GlaxoSmithKline received approval from the FDA for its Biologics License Application (BLA) for Nucala (mepolizumab) as an add-on maintenance treatment...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/10/16

    Study of Nucala (subcutaneous mepolizumab) in eosinophilic asthma published in Journal of Allergy and Clinical Immunology- GlaxoSmithKline

    GlaxoSmithKline has announced the publication of a meta-analysis in the Journal of Allergy and Clinical Immunology, which demonstrates that the...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/06/15

    FDA advisory Committee recommends mepolizumab for treatment of severe/ eosinophilic asthma- GSK

    GSK reported that the meeting of the Pulmonary Allergy Drugs Advisory Committee of the FDA has voted unanimously that the...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    14/01/24

    Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype.- GSK plc.

    GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/12/15

    EU approves Nucala (mepolizumab) as a treatment for severe refractory eosinophilic asthma- GSK

    GlaxoSmithKline announced that the European Commission has granted marketing authorisation for Nucala (mepolizumab) as an add-on treatment for severe refractory...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/09/15

    EU CHMP recommends approval of Nucala (mepolizumab) for eosinophilic asthma- GlaxoSmithKline

    GlaxoSmithKline announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued...

    See more